Sarepta Therapeutics Inc. has added Henri Termeer, former chief
executive of Genzyme Corp., as an adviser as the biotechnology
company seeks approval for its muscular-dystrophy drug.
Shares increased by about 1.8% in light premarket trading.
"I am honored to have Henri Termeer, a pioneer of rare disease
companies, serve as an adviser as we seek FDA approval for our lead
product candidate and build a rare disease organization," said
Edward Kaye, Sarepta's interim CEO.
The Cambridge, Mass., company has been in transition in recent
months. Former chief executive Chris Garabedian resigned in April,
just as the company was poised to seek FDA approval for a widely
anticipated drug, eteplirsen, for treating a Duchenne muscular
dystrophy, a rare genetic disorder.
http://blogs.wsj.com/pharmalot/2015/04/01/sarepta-therapeutics-ceo-resigns-amid-tumult-with-the-fda/
Mr. Garabedian's departure came after Sarepta appeared to have
angered the FDA with a news release about the approval process for
its drug. When asked why Mr. Garabedian departed so abruptly,
interim chairman John Hodgson said, "it's really about going in a
different direction ... to ensure we have the best opportunity with
the FDA" to receive approval.
http://www.wsj.com/articles/sarepta-shares-surge-on-plans-to-file-dystrophy-drug-1432071223
In May, Sarepta said following a meeting with the U.S. Food and
Drug Administration that it still planned to start the process of
getting regulatory approval for its treatment.
Mr. Termeer worked at Genzyme for 30 years before retiring in
2011 after it was purchased by Sanofi S.A.
Write to Angela Chen at angela.chen@dowjones.com
Access Investor Kit for Sanofi
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=FR0000120578
Access Investor Kit for Sanofi
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=US80105N1054
Access Investor Kit for Sarepta Therapeutics, Inc.
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=US8036071004
Subscribe to WSJ: http://online.wsj.com?mod=djnwires